[go: up one dir, main page]

BR9507055A - Composições orais liquidas contendo resinado de paroxetina - Google Patents

Composições orais liquidas contendo resinado de paroxetina

Info

Publication number
BR9507055A
BR9507055A BR9507055A BR9507055A BR9507055A BR 9507055 A BR9507055 A BR 9507055A BR 9507055 A BR9507055 A BR 9507055A BR 9507055 A BR9507055 A BR 9507055A BR 9507055 A BR9507055 A BR 9507055A
Authority
BR
Brazil
Prior art keywords
resin
compositions containing
oral compositions
liquid oral
containing paroxetine
Prior art date
Application number
BR9507055A
Other languages
English (en)
Inventor
Graham Stanley Leonard
David Cooper
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9507055A publication Critical patent/BR9507055A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR9507055A 1994-02-03 1995-01-30 Composições orais liquidas contendo resinado de paroxetina BR9507055A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9402029A GB9402029D0 (en) 1994-02-03 1994-02-03 Novel formulation
PCT/EP1995/000319 WO1995020964A1 (en) 1994-02-03 1995-01-30 Oral liquid compositions containing paroxetine resinate

Publications (1)

Publication Number Publication Date
BR9507055A true BR9507055A (pt) 1997-09-02

Family

ID=10749765

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9507055A BR9507055A (pt) 1994-02-03 1995-01-30 Composições orais liquidas contendo resinado de paroxetina

Country Status (34)

Country Link
US (1) US5811436A (pt)
EP (1) EP0742715B1 (pt)
JP (1) JP4445590B2 (pt)
CN (1) CN1074922C (pt)
AP (2) AP611A (pt)
AT (1) ATE178489T1 (pt)
AU (1) AU682091B2 (pt)
BG (1) BG62843B1 (pt)
BR (1) BR9507055A (pt)
CA (1) CA2182593A1 (pt)
CZ (1) CZ285128B6 (pt)
DE (1) DE69508924T2 (pt)
DK (1) DK0742715T3 (pt)
DZ (1) DZ1850A1 (pt)
ES (1) ES2129806T3 (pt)
FI (1) FI118205B (pt)
GB (1) GB9402029D0 (pt)
GR (1) GR3030131T3 (pt)
HK (1) HK1012288A1 (pt)
HU (1) HUT75941A (pt)
IL (1) IL112521A (pt)
MA (1) MA23441A1 (pt)
MX (1) MX9603203A (pt)
MY (1) MY113036A (pt)
NO (1) NO307954B1 (pt)
NZ (1) NZ278891A (pt)
OA (1) OA10446A (pt)
PL (1) PL178331B1 (pt)
RO (1) RO116342B1 (pt)
RU (1) RU2136281C1 (pt)
SK (1) SK281214B6 (pt)
TW (1) TW436296B (pt)
WO (1) WO1995020964A1 (pt)
ZA (1) ZA95776B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
EP1078925A1 (en) 1997-06-10 2001-02-28 Synthon B.V. 4-Phenylpiperidine compounds
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
EP1250937B1 (en) * 2001-04-09 2009-05-13 Rohm And Haas Company Controlled dissolution of active ingredients
US20020176842A1 (en) * 2001-04-09 2002-11-28 Lyn Hughes Extended release of active ingredients
US6906206B2 (en) * 2001-04-30 2005-06-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
GB0119467D0 (en) * 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
US20040242497A1 (en) * 2001-08-09 2004-12-02 Barges Causeret Nathalie Claude Marianne Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
US20060063737A1 (en) * 2004-08-18 2006-03-23 Holmdahl Lisa K Liquid paroxetine compositions
EP1791531A1 (en) * 2004-08-20 2007-06-06 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) * 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
CA2629514A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
CN102430122A (zh) * 2005-12-13 2012-05-02 量子高科(北京)研究院有限公司 盐酸氟西汀口腔崩解片及其制备方法
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20100273822A1 (en) * 2009-04-22 2010-10-28 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins
US8758779B2 (en) 2009-06-25 2014-06-24 Wockhardt Ltd. Pharmaceutical composition of duloxetine
US8187617B2 (en) * 2009-09-11 2012-05-29 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments
EP2572717B1 (en) 2010-05-19 2016-06-15 Astellas Pharma Inc. Pharmaceutical composition containing solifenacin
CN104027306A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 帕罗西汀口服混悬液及其制备方法
GB201419261D0 (en) 2014-10-29 2014-12-10 Therakind Ltd Formulations
CN104382870A (zh) * 2014-10-30 2015-03-04 万全万特制药江苏有限公司 一种含有波拉克林钾-帕罗西汀的复合物
CN106309363A (zh) * 2016-09-24 2017-01-11 万特制药(海南)有限公司 盐酸帕罗西汀口服混悬液及其制备方法
CN108926528A (zh) * 2017-05-25 2018-12-04 北京万全德众医药生物技术有限公司 含有氨磺必利树脂酸盐的口服液体组合物
CA3128377A1 (en) 2019-02-01 2020-08-06 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy
CN113209017B (zh) * 2021-06-02 2023-06-20 上海美优制药有限公司 一种盐酸帕罗西汀混悬剂及其制备方法
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB9005498D0 (en) * 1990-03-12 1990-05-09 Beecham Group Plc Composition
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.

Also Published As

Publication number Publication date
DE69508924T2 (de) 1999-10-21
US5811436A (en) 1998-09-22
SK100496A3 (en) 1996-12-04
BG100763A (bg) 1997-03-31
RU2136281C1 (ru) 1999-09-10
NO963244D0 (no) 1996-08-02
NZ278891A (en) 1998-01-26
AP611A (en) 1997-09-03
RO116342B1 (ro) 2001-01-30
DK0742715T3 (da) 1999-10-18
CN1140411A (zh) 1997-01-15
GR3030131T3 (en) 1999-07-30
ES2129806T3 (es) 1999-06-16
MA23441A1 (fr) 1995-10-01
BG62843B1 (bg) 2000-09-29
FI963051L (fi) 1996-08-01
CN1074922C (zh) 2001-11-21
MX9603203A (es) 1997-03-29
EP0742715B1 (en) 1999-04-07
HUT75941A (en) 1997-05-28
PL178331B1 (pl) 2000-04-28
AP9600839A0 (en) 1996-07-31
ZA95776B (en) 1996-08-01
NO963244L (no) 1996-08-02
WO1995020964A1 (en) 1995-08-10
CA2182593A1 (en) 1995-08-10
DE69508924D1 (de) 1999-05-12
AP9500715A0 (en) 1995-04-30
EP0742715A1 (en) 1996-11-20
IL112521A0 (en) 1995-05-26
HK1012288A1 (en) 1999-07-30
JP4445590B2 (ja) 2010-04-07
ATE178489T1 (de) 1999-04-15
SK281214B6 (sk) 2001-01-18
AU682091B2 (en) 1997-09-18
CZ229396A3 (en) 1997-01-15
DZ1850A1 (fr) 2002-02-17
CZ285128B6 (cs) 1999-05-12
OA10446A (en) 2002-03-26
PL315679A1 (en) 1996-11-25
HU9602151D0 (en) 1996-09-30
TW436296B (en) 2001-05-28
FI118205B (fi) 2007-08-31
NO307954B1 (no) 2000-06-26
IL112521A (en) 1999-09-22
GB9402029D0 (en) 1994-03-30
JPH09508402A (ja) 1997-08-26
AU1536895A (en) 1995-08-21
FI963051A0 (fi) 1996-08-01
MY113036A (en) 2001-11-30
AP536A (en) 1996-09-26

Similar Documents

Publication Publication Date Title
BR9507055A (pt) Composições orais liquidas contendo resinado de paroxetina
ATE284695T1 (de) Oral anzuwendende arzneizusammensetzung enthaltend 2-methyl-thienobenzodiazepin
BR9508844A (pt) Composição oral
DE69503861D1 (de) Laserbeschriftbare Harzzusammensetzung
DE69518950D1 (de) Klebende Organopolysiloxanzusammensetzungen
CY2005007I1 (el) Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
FI963421A0 (fi) Oraalisia apuainekoostumuksia
DE69512647D1 (de) Durchsichtiges flüssiges zahnputzmittel
TR199501325A2 (tr) Protez dis sabitlestirme terkipleri.
BR9506536A (pt) Composição oral
FI972168L (fi) Oraaliset koostumukset, jotka sisältävät ondansetronia
ATE245451T1 (de) Xanthangummi enthaltende gelbildende ophthalmische zusammensetzungen
BR9509200A (pt) Composição de matéria
BR9503334A (pt) Composiçao de resina de policarbonato
BR9508661A (pt) Composições dentárias de custo efetivo contendo novos aluminosilicatos de sódio
ATE260659T1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
BR9510467A (pt) Composições orais
DE69513309D1 (de) Epoxydharzzusammensetzung
DE69501378D1 (de) Harzzusammensetzung
ITMI982222A0 (it) Composizioni farmaceutiche orali contenenti buprenorfina
KR970703779A (ko) 건강 조성물(health composition)
FI953076L (fi) Zirkoniumyhdisteitä sisältäviä koostumuksia
BR9510307A (pt) Composições orais
BR9606974A (pt) Composições orais
MA23731A1 (fr) Compositions detegentes

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 31/445; A61K 9/00; A61K 47/48.

Ipc: A61K 9/00 (2006.01), A61K 31/445 (2006.01), A61K 3

Ipc: A61K 9/00 (2006.01), A61K 31/445 (2006.01), A61K 3

B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A, 17A, 18A, 19A E 20A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.